AnaptysBio (ANAB) CEO adjusts and receives new stock option grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ANAPTYSBIO, INC President and CEO Daniel Faga reported compensation-related stock option changes rather than open-market share trades. On April 20, 2026, he both acquired and disposed of multiple employee stock options covering shares of AnaptysBio common stock.

Footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted so it became an option on both companies’ shares. As a result, Faga acquired new options to buy AnaptysBio common stock at exercise prices such as $10.87, $15.53, $17.02, $22.31, and $32.17 per share, with corresponding dispositions of prior awards back to the issuer.

Several of these options are described as fully vested or vesting 25% on specific January dates with the balance vesting in equal monthly installments over 48 months, contingent on his continued service. The filing reflects grants, adjustments, and issuer-related dispositions of options, not open-market buying or selling of common stock.

Insider Trade Summary

14 transactions reported

Mixed 14 txns

Insider Faga Daniel

Role President, CEO

Type	Security	Shares	Price	Value
Disposition	Employee Stock Option (right to buy)	11,000	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	11,000	$0.00	--
Disposition	Employee Stock Option (right to buy)	2,321	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	2,321	$0.00	--
Disposition	Employee Stock Option (right to buy)	9,200	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	9,200	$0.00	--
Disposition	Employee Stock Option (right to buy)	194,900	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	194,900	$0.00	--
Disposition	Employee Stock Option (right to buy)	379,620	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	379,620	$0.00	--
Disposition	Employee Stock Option (right to buy)	305,500	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	305,500	$0.00	--
Disposition	Employee Stock Option (right to buy)	133,400	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	133,400	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 16,510 shares (Direct, null)

Footnotes (1)

Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. The stock option is fully vested and exercisable. The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Option grant shares: 133,400 options Option grant shares: 305,500 options Option grant shares: 379,620 options +4 more

7 metrics

Option grant shares 133,400 options Employee Stock Option with $32.17 exercise price, expiration 2036-01-06

Option grant shares 305,500 options Employee Stock Option with $10.87 exercise price, expiration 2035-01-06

Option grant shares 379,620 options Employee Stock Option with $15.53 exercise price, expiration 2034-01-02

Option grant shares 194,900 options Employee Stock Option with $17.02 exercise price, expiration 2033-01-05

Option grant shares 9,200 options Employee Stock Option with $22.31 exercise price, expiration 2032-02-09

Vesting schedule 25% then 1/48 monthly One option vests 25% on January 6, 2024; remainder monthly over 48 months

Vesting schedule 25% then 1/48 monthly Another option vests 25% on January 3, 2025; remainder monthly over 48 months

Key Terms

Separation and Distribution Agreement, pro rata distribution, Employee Stock Option (right to buy), Disposition to issuer, +2 more

6 terms

Separation and Distribution Agreement regulatory

"pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks"

pro rata distribution financial

"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock"

A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.

Employee Stock Option (right to buy) financial

"security_title": "Employee Stock Option (right to buy)""

Disposition to issuer financial

"transaction_code_description": "Disposition to issuer""

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

vesting financial

"thereafter vests as to 1/48 of the total shares monthly until fully vested"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

04/22/2026 - 06:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faga Daniel

(Last)

(First)

(Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$31.12	04/20/2026		D⁽¹⁾			11,000	⁽²⁾	11/25/2031	Common Stock	16,510	$0	16,510	D
Employee Stock Option (right to buy)	$22.8	04/20/2026		A⁽¹⁾		11,000		⁽²⁾	11/25/2031	Common Stock	11,000	$0	11,000	D
Employee Stock Option (right to buy)	$31.12	04/20/2026		D⁽¹⁾			2,321	⁽²⁾	11/25/2031	Common Stock	2,321	$0	2,321	D
Employee Stock Option (right to buy)	$22.8	04/20/2026		A⁽¹⁾		2,321		⁽²⁾	11/25/2031	Common Stock	2,321	$0	2,321	D
Employee Stock Option (right to buy)	$30.44	04/20/2026		D⁽¹⁾			9,200	⁽²⁾	02/09/2032	Common Stock	9,200	$0	9,200	D
Employee Stock Option (right to buy)	$22.31	04/20/2026		A⁽¹⁾		9,200		⁽²⁾	02/09/2032	Common Stock	9,200	$0	9,200	D
Employee Stock Option (right to buy)	$23.23	04/20/2026		D⁽¹⁾			194,900	⁽³⁾	01/05/2033	Common Stock	194,900	$0	194,900	D
Employee Stock Option (right to buy)	$17.02	04/20/2026		A⁽¹⁾		194,900		⁽³⁾	01/05/2033	Common Stock	194,900	$0	194,900	D
Employee Stock Option (right to buy)	$21.19	04/20/2026		D⁽¹⁾			379,620	⁽⁴⁾	01/02/2034	Common Stock	379,620	$0	379,620	D
Employee Stock Option (right to buy)	$15.53	04/20/2026		A⁽¹⁾		379,620		⁽⁴⁾	01/02/2034	Common Stock	379,620	$0	379,620	D
Employee Stock Option (right to buy)	$14.83	04/20/2026		D⁽¹⁾			305,500	⁽⁵⁾	01/06/2035	Common Stock	305,500	$0	305,500	D
Employee Stock Option (right to buy)	$10.87	04/20/2026		A⁽¹⁾		305,500		⁽⁵⁾	01/06/2035	Common Stock	305,500	$0	305,500	D
Employee Stock Option (right to buy)	$43.91	04/20/2026		D⁽¹⁾			133,400	⁽⁶⁾	01/06/2036	Common Stock	133,400	$0	133,400	D
Employee Stock Option (right to buy)	$32.17	04/20/2026		A⁽¹⁾		133,400		⁽⁶⁾	01/06/2036	Common Stock	133,400	$0	133,400	D

Explanation of Responses:

1. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.

2. The stock option is fully vested and exercisable.

3. The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

4. The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

5. The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

6. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Dan Faga	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AnaptysBio (ANAB) CEO Daniel Faga report in this Form 4?

Daniel Faga reported grants, adjustments, and related dispositions of employee stock options, not open-market stock trades. These derivative awards give rights to buy AnaptysBio common shares at set exercise prices and follow specific vesting schedules tied to continued service with the company.

How is the Separation and Distribution Agreement affecting ANAB CEO stock options?

The Separation and Distribution Agreement between AnaptysBio and First Tracks caused each outstanding option to be adjusted into options on both companies’ shares. As a result, Daniel Faga acquired new options to buy AnaptysBio common stock in amounts determined under that Separation Agreement’s terms.

Were there any open-market purchases or sales of ANAB common stock in this filing?

No open-market purchases or sales of AnaptysBio common stock are shown. The transactions all involve employee stock options, including grants and dispositions to the issuer. They represent compensation and structural adjustments rather than trading of already-issued common shares on the open market.

What exercise prices are associated with Daniel Faga’s ANAB stock options here?

The options reported include exercise prices such as $10.87, $15.53, $17.02, $22.31, $22.80, $31.12, $32.17, $30.44 and $43.91 per share. Each option specifies a distinct strike price, expiration date and vesting pattern governing when and how the award can be exercised.

How do the CEO’s AnaptysBio options vest according to this Form 4?

Several options vest 25% on a specified January date, such as January 6, 2024 or later years, then 1/48 of the total shares monthly until fully vested. Vesting depends on Daniel Faga continuing to provide services to AnaptysBio on each scheduled vesting date.

What do the disposition transactions in this ANAB Form 4 represent?

Disposition transactions with code D indicate options returned or adjusted back to the issuer rather than sold in the market. They correspond to prior awards being replaced or modified as part of the separation-related adjustments, alongside newly acquired options on AnaptysBio common stock.